Rheumatoid Arthritis & Gut Health

Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects roughly 1 in 100 people worldwide. Unlike osteoarthritis — which is driven primarily by mechanical wear — RA is an immune-mediated condition in which the body’s own defences mistakenly attack the lining of the joints, causing pain, swelling, stiffness, and, if left unchecked, irreversible joint damage.

Most people with RA are told the cause is unknown and that the aim of treatment is to suppress the immune system. But over the past decade, a remarkable body of research has emerged pointing to the gut — specifically the gut microbiome — as a critical environmental trigger in RA pathogenesis. This isn’t fringe science. It is appearing in Nature, Nature Reviews Rheumatology, and some of the world’s most rigorous peer-reviewed journals.

In this article, I want to walk you through what that research actually says: which bacteria are implicated, how a leaky gut may drive joint inflammation, why the immune imbalance in RA is rooted in the gut, and what this means practically for your diet, testing, and supplement choices.

What Is Rheumatoid Arthritis?

RA is characterised by chronic inflammation of the synovial membrane — the tissue that lines the joints. This triggers a cascade of immune activity that destroys cartilage and erodes bone. The hallmark features include:

• Symmetrical joint pain and swelling, most commonly hands and feet
• Morning stiffness lasting more than 30 minutes
• Fatigue and systemic inflammation
• Elevated inflammatory markers (CRP, ESR)
• Positive rheumatoid factor (RF) and/or anti-CCP antibodies in the majority of cases

What makes RA particularly interesting from a functional medicine perspective is the preclinical phase — a period of months to years before joint symptoms appear, during which immune dysregulation, autoantibodies, and mucosal changes are already underway. This window is increasingly where gut-related research is focused, because it suggests that intervention early — at the level of the gut — may actually be able to shift disease trajectory.

The Gut-Joint Axis: An Overview

The concept of a gut-joint axis describes the bidirectional communication between the intestinal microbiome, the gut immune system, and the joints. It is now well-established in the literature that dysbiosis — an imbalance in the microbial communities of the gut — can trigger and perpetuate systemic autoimmune responses that manifest in the joints.

A 2021 review in Nature Reviews Rheumatology by Zaiss and colleagues described the gut-joint axis in detail, noting that alterations in microbial composition at mucosal sites (gut, mouth, lungs) precede the onset of clinical RA and may represent some of the earliest detectable events in disease pathogenesis.¹

Another key review in Microbiome Research Reports documented that gut dysbiosis precedes arthritis and that local intestinal inflammation leads to systemic inflammation in genetically predisposed individuals.² The mechanistic links involve three primary pathways:

• Inflammatory immune activation — pathogenic bacteria driving pro-inflammatory T cell responses
• Molecular mimicry — bacterial antigens that resemble joint tissue, triggering autoantibody production
• Loss of intestinal barrier integrity — ‘leaky gut’ allowing bacterial components to enter the bloodstream

Critically, a 2026 review in Microbiome Research Reports concluded that the literature supports a mechanistic link between gut dysbiosis and RA onset, and that microbiota-targeted strategies — including dietary interventions, probiotics, and prebiotics — show early potential in restoring microbial balance and reducing inflammatory markers.²

The Microbiome in RA: What Does the Research Show?

Reduced Diversity

One of the most consistent findings across multiple studies is that RA patients have significantly reduced gut microbial diversity compared to healthy controls. A 2025 study analysing 262 RA patients and 475 healthy controls using high-throughput 16S rRNA sequencing found that RA patients had notably lower alpha-diversity — meaning fewer distinct species — and distinct structural differences in microbial composition.⁴

Diversity matters because a diverse microbiome is a resilient microbiome. Fewer species means fewer pathways for producing anti-inflammatory compounds, fewer bacterial checks and balances, and greater vulnerability to the kinds of imbalances that can fuel autoimmunity.

Prevotella copri: The Most Studied Bacterial Suspect

The bacterium that has received the most research attention in the context of RA is Prevotella copri. In a landmark 2013 study published in eLife, Scher and colleagues demonstrated that P. copri was significantly expanded in the guts of patients with new-onset, untreated RA compared to healthy controls, patients with chronic RA, and those with psoriatic arthritis.⁵

The significance of ‘new-onset untreated’ is important — it suggests this expansion is an early event, not simply a consequence of medication or chronic disease. Subsequent research confirmed immune relevance: P. copri-derived peptides have been shown to stimulate Th1 immune responses in 42% of new-onset RA patients, and antibodies to P. copri proteins have been detected in RA serum.⁶

Importantly, a 2022 study in Cell & Molecular Immunology showed that in the presence of P. copri colonisation, a high-fibre diet actually exacerbated arthritis in an animal model. This is a critical nuance: high-fibre diets are generally anti-inflammatory, but if P. copri is overabundant, that fibre may feed the wrong bacteria, leading to overproduction of inflammatory organic acids including succinate and fumarate.⁷ This illustrates why a personalised microbiome assessment matters enormously in RA — blanket dietary advice can backfire.

Collinsella and Other Pathobionts

Beyond Prevotella, a consistent finding in the literature is an expansion of Collinsella aerofaciens in RA patients. Collinsella has been shown to increase intestinal permeability and promote inflammatory cytokine production, particularly IL-17A — a key driver of joint inflammation in RA.

Other overrepresented bacteria in RA microbiome studies include Eggerthella lenta and certain Lactobacillus species. Meanwhile, bacteria associated with immune tolerance tend to be depleted, including Bacteroides fragilis, Faecalibacterium prausnitzii, Haemophilus spp., and Eubacterium spp.²

A 2022 comprehensive review in Frontiers in Immunology summarised that the RA microbiome is characterised by a state of increased pathobionts and depleted commensals — the very bacteria responsible for producing short-chain fatty acids (SCFAs) and maintaining immune homeostasis.⁸

Leaky Gut, Zonulin, and Rheumatoid Arthritis

One of the most important mechanisms connecting gut health to RA is intestinal hyperpermeability — commonly called ‘leaky gut’. The gut lining is just one cell thick, held together by tight junction proteins including occludin, claudin-1, and ZO-1 (zonula occludens-1). These tight junctions act as gatekeepers, deciding what crosses from the intestinal lumen into the bloodstream.

When these junctions break down, bacterial components — including lipopolysaccharide (LPS), bacterial DNA, and flagellin — can translocate into systemic circulation, triggering immune activation and inflammation far beyond the gut.

Zonulin as a Predictive Biomarker

Zonulin is a protein secreted by gut epithelial cells that regulates tight junction permeability. A groundbreaking 2020 study in Nature Communications found that elevated serum zonulin levels can predict the transition from asymptomatic autoimmunity to clinical inflammatory arthritis. In autoimmune-prone mice, increased zonulin was accompanied by dysbiosis and intestinal barrier disruption — and crucially, restoring barrier integrity using butyrate or a cannabinoid receptor agonist inhibited the onset of arthritis.⁹

The same research group showed that a zonulin antagonist administered during the pre-arthritis phase prevented disease development — a finding with significant therapeutic implications.

Clinical Evidence in RA Patients

A 2024 cross-sectional study in International Journal of Molecular Sciences directly measured tight junction proteins in RA patients compared to healthy controls. Claudin-1 levels showed significant differences between groups, and RA patients had lower microbial diversity alongside higher inflammatory markers (CRP, IL-6, TNF-alpha).¹⁰

A comprehensive 2024 review explicitly listed RA alongside IBD, ankylosing spondylitis, hepatitis, and lupus as systemic inflammatory diseases that a damaged intestinal barrier can facilitate. The authors noted that in collagen-induced arthritis models, intestinal permeability was elevated — and tight junction protein expression was reduced — before the onset of arthritis itself.¹¹

This is not merely correlational. The research is building a mechanistic, time-ordered story: gut dysbiosis → intestinal permeability → bacterial translocation → systemic immune activation → joint inflammation.

The Immune Connection: Th17/Treg Imbalance

Perhaps the most important immunological concept in RA is the imbalance between Th17 cells (pro-inflammatory) and regulatory T cells (Tregs) (anti-inflammatory and immune tolerant). In healthy individuals, Tregs keep Th17 activity in check. In RA, this balance is skewed — too much Th17 activity drives synovial inflammation, cartilage destruction, and autoantibody production.

The gut microbiome has a profound influence on this balance. Specifically, butyrate and other short-chain fatty acids (SCFAs) — produced when beneficial gut bacteria ferment dietary fibre — are the primary modulators of the Th17/Treg axis.

Short-Chain Fatty Acids: The Anti-Inflammatory Metabolites

A 2025 systematic review synthesised preclinical and clinical evidence showing that SCFAs (acetate, propionate, butyrate) modulate the Th17/Treg balance via three mechanisms:

• Metabolic reprogramming via AMPK/mTOR signalling pathways
• Epigenetic regulation through inhibition of histone deacetylase (HDAC) enzymes
• Modulation of cytokine cascades including IL-10, IL-1β, and TNF-alpha

The review noted that SCFAs can suppress NLRP3 inflammasome activation, resulting in a 70% decrease in IL-1β levels in preclinical models, while enhancing Treg function with a threefold increase in IL-10 — the key anti-inflammatory cytokine. High-fibre diets that increase butyrate production by 240% were associated with a reduction in Disease Activity Score of 1.8 points.¹²

Even more striking: butyrate exhibits circadian fluctuations that negatively correlate with morning stiffness severity — suggesting that supporting butyrate production could be relevant even to the timing of symptoms.¹²

SCFA-Producing Bacteria: The Depleted Heroes

The bacteria most responsible for producing SCFAs — including Faecalibacterium prausnitzii, Roseburia intestinalis, and Eubacterium rectale — are consistently reduced in RA patients.⁸ This means RA patients are chronically under-producing the very metabolites that would otherwise dampen their immune response. It is a self-perpetuating cycle: dysbiosis reduces SCFAs, which removes immune brakes, which allows Th17-driven inflammation to accelerate, which may further damage the gut lining.

SIBO and Rheumatoid Arthritis

Small intestinal bacterial overgrowth (SIBO) — the abnormal proliferation of bacteria in the small intestine — is an underappreciated factor in the RA picture. Bacteria that belong in the large intestine migrating upwards into the small intestine can drive local inflammation, impair nutrient absorption, and contribute to systemic immune activation.

A direct study published in Annals of the Rheumatic Diseases found that a high frequency of SIBO was present in RA patients, and crucially, disease activity indices and rheumatoid factor titres were significantly higher in RA patients with SIBO than in those without — a finding that was independent of gastric acid status.¹³

This finding makes physiological sense. RA patients are frequently treated with NSAIDs and sometimes proton pump inhibitors (PPIs) — both of which alter gut motility and gastric acid secretion respectively, creating conditions favourable to bacterial overgrowth. DMARDs such as methotrexate can also alter gut microbial composition. The research now indicates that anti-rheumatic medications produce measurable shifts in gut microbial structure — meaning the treatment itself can further compound dysbiosis.²

If SIBO is present and unaddressed, gut-targeted interventions — including probiotics and fibre strategies — may have limited effect or even be counterproductive, depending on the type of overgrowth. This is why breath testing is an important clinical tool in patients with RA who also experience digestive symptoms.

Diet, the Gut Microbiome, and RA Disease Activity

Diet is one of the most powerful modulators of gut microbiome composition, and therefore one of the most accessible levers for influencing RA through the gut-joint axis. Here is what the evidence shows.

The Mediterranean Diet

The Mediterranean diet is the most studied dietary pattern in the context of RA and gut health. A 2020 study in Microorganisms directly examined 60 RA patients, splitting them by adherence to the Mediterranean diet using the validated PREDIMED questionnaire and profiling their gut microbiota using 16S rRNA sequencing. Patients with high Mediterranean diet adherence had significantly different microbiota profiles and lower disease activity scores.¹⁴

A 2020 narrative review in Nutrients concluded that the Mediterranean diet may act as an adjuvant therapeutic approach in RA by modulating intestinal microbiota and intestinal barrier function. The mechanisms include increased SCFA-producing bacteria, higher antioxidant intake, anti-inflammatory omega-3 fatty acids from fish and olive oil, and polyphenols that selectively feed beneficial Lactobacillus and Bifidobacterium species.¹⁵

Dietary Fibre and Butyrate

The data on fibre is nuanced but broadly supportive. In RA patients without P. copri overgrowth, high-fibre diets consistently support SCFA production and reduce inflammatory markers. Given the evidence that high-fibre diets can increase butyrate by 240% and reduce DAS28 scores, dietary fibre is an important consideration.¹²

However — and this is an important clinical nuance — in patients where P. copri is overabundant, the same fibre can fuel harmful fermentation pathways producing excess succinate, which drives inflammation. This is precisely why microbiome testing before starting a high-fibre protocol matters clinically.

Foods to Prioritise

• Oily fish (salmon, mackerel, sardines) — omega-3 fatty acids reduce synovial inflammation
• Extra virgin olive oil — oleuropein and oleocanthal have anti-inflammatory properties
• Colourful vegetables and fruits — polyphenols support beneficial bacterial diversity
• Fermented foods (kefir, sauerkraut, kimchi) — if tolerated, provide live bacteria and support diversity
• Legumes and cooked-and-cooled starches — resistant starch feeds SCFA-producing bacteria

Foods to Reduce

• Ultra-processed foods — deplete bacterial diversity and increase intestinal permeability
• Processed meat — associated with higher inflammatory markers and reduced Bacteroidetes
• Refined sugar and high-fructose corn syrup — selectively feeds pathobionts
• Excessive alcohol — directly damages tight junction proteins

Probiotics in RA: What the Clinical Trials Show

The clinical evidence for probiotics in RA is growing — but it requires careful interpretation. The most robust data to date comes from a 2022 systematic review and meta-analysis published in Nutrients, which examined 8 randomised controlled trials in 344 RA patients. The meta-analysis found a statistically significant reduction in C-reactive protein (CRP) with probiotic supplementation.¹⁶

A 2022 meta-analysis in Frontiers in Immunology analysed 34 RCTs across 8 types of inflammatory arthritis and found that in the 10 RA trials (632 participants), probiotic intervention reduced CRP levels — supporting the view that the gut-immune interface is modifiable through targeted microbial intervention.¹⁷

The most studied strains in RA include Lactobacillus casei, Lactobacillus acidophilus, Bifidobacterium bifidum, and Bacillus coagulans. A foundational RCT found that 8 weeks of Lactobacillus casei 01 supplementation significantly decreased disease activity score in RA patients compared to placebo.¹⁸

It is important to note that the evidence base, while promising, is still limited by small sample sizes and heterogeneity of strains and dosages. No single probiotic strain can yet be recommended as a standalone RA treatment. However, as part of a broader gut-focused approach, specific targeted probiotics have a well-supported rationale.

Key Supplements with Evidence in RA and Gut Health

Butyrate

Given the central role of butyrate in restoring the Th17/Treg balance and supporting intestinal barrier integrity, direct butyrate supplementation is a rational intervention when dietary fibre alone is insufficient. Butyrate inhibits HDAC enzymes, promotes Foxp3+ Treg differentiation, and directly reduces synovial inflammation in preclinical arthritis models.¹²

Recommended Products: Sodium Butyrate and PHGG (a prebiotic that feeds butyrate producing bacteria)

Omega-3 Fatty Acids (EPA/DHA)

EPA and DHA have multiple mechanisms of action in RA: they produce anti-inflammatory eicosanoids (resolvins, protectins), reduce TNF-alpha and IL-6, and support gut microbiome diversity and intestinal barrier function. Multiple meta-analyses support their use in RA to reduce joint pain and morning stiffness.

Recommended Product: Life & Soul

Curcumin

Curcumin is beneficial for rheumatoid arthritis treatment. Inflammation levels and clinical symptoms in patients with rheumatoid arthritis can be improved by curcumin supplementation

Recommended Product: Curcumin

L-Glutamine

Glutamine is the primary fuel source for intestinal epithelial cells and a critical nutrient for tight junction maintenance. Under conditions of systemic inflammation — as in RA — glutamine becomes conditionally essential, and supplementation supports gut barrier integrity.

Recommended Product: Rezcue (includes zinc carnosine)

Vitamin D

Vitamin D is a recognised immunomodulatory nutrient with specific evidence in autoimmune disease. It supports Treg differentiation, inhibits Th17 activity, and vitamin D deficiency is prevalent in RA patients. Optimising vitamin D to a functional level (75–100 nmol/L) should be considered a foundational step.

Recommended Product: D3/K2

Zinc and Magnesium

Zinc is required for tight junction protein expression and immune regulation. Magnesium supports over 300 enzymatic processes including those involved in inflammatory resolution. Both are commonly depleted in individuals with chronic inflammatory conditions and poor gut absorption.

Recommended Product: Magnesium Glycinate (see Rezcue for a great zinc-glutamine combo)

Putting It All Together: A Functional Medicine Approach to RA

The research is clear: the gut is not peripheral to RA — it may be central to it. A functional medicine approach to RA alongside conventional treatment considers the following steps:

• Assess gut microbiome composition with a comprehensive stool test
• Rule out SIBO/IMO with breath testing if digestive symptoms are present
• Remove dietary triggers of dysbiosis (ultra-processed food, refined sugars, excessive alcohol)
• Adopt a Mediterranean-style dietary pattern rich in polyphenols, omega-3s, and diverse plant foods
• Support SCFA production through prebiotic fibres — adjusted based on microbiome findings
• Use targeted probiotics appropriate to your identified microbial imbalances
• Support the intestinal barrier with butyrate, L-glutamine, and zinc
• Optimise vitamin D to a functional level
• Work with a practitioner who can interpret functional labs and personalise your protocol

This approach does not replace your rheumatologist or your DMARDs. What it does is address the upstream drivers that may be perpetuating immune dysregulation — giving your body a better environment in which to respond to treatment.

What to Test

Ultimate Gut Health Test

A comprehensive gut microbiome analysis provides a detailed snapshot of your large intestinal bacterial communities. It can identify pathobiont overgrowths (such as P. copri), depletions in SCFA-producing bacteria (such as Faecalibacterium prausnitzii), markers of intestinal barrier function, and inflammatory markers. This information is invaluable for personalising dietary and supplement protocols in RA.

Struggling with symptoms?.

Shop our gut health tests

SIBO/IMO Breath Test

If you experience bloating, excessive gas, abdominal discomfort, altered bowel habits, or nutritional deficiencies alongside RA, SIBO or intestinal methanogen overgrowth (IMO) should be ruled out. The breath test measures hydrogen and methane gas produced by bacterial fermentation in the small intestine and is non-invasive, performed at home. Given the documented association between SIBO and higher RA disease activity, this is a clinically justified test in the right patient.

A Note on Working with Your Rheumatologist

Everything discussed in this article is intended to complement — not replace — your conventional rheumatology care. Disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate, leflunomide, and biologics remain the gold-standard for preventing joint damage and disability. What the gut research offers is an additional lens: one that may help explain why some patients respond better than others, and where personalised nutritional and microbiome support may improve outcomes alongside medication.

Always discuss changes to your diet, supplements, or lifestyle with your rheumatologist and any functional medicine practitioner you work with collaboratively.

References

1. Zaiss MM, Joyce Wu HJ, Mauro D, Schett G, Ciccia F. The gut-joint axis in rheumatoid arthritis. Nat Rev Rheumatol. 2021;17(4):224-237. doi: 10.1038/s41584-021-00585-3. PMID: 33674813
2. Poznyak AV et al. An overview of the role of the gut microbiota in rheumatoid arthritis. Microbiome Res Rep. 2026;5(1):3. doi: 10.20517/mrr.2025.69. PMID: 42007373
3. (See ref 2)
4. Wang et al. A predictive model based on the gut microbiota improves the diagnostic effect in patients with rheumatoid arthritis. 2025. PMID: 39873731
5. Scher JU, Sczesnak A, Longman RS, et al. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. eLife. 2013;2:e01202. doi: 10.7554/eLife.01202. PMID: 24192039
6. Pianta A, Arvikar SL, Strle K, et al. Evidence of immune relevance of Prevotella copri, a gut microbe, in patients with rheumatoid arthritis. Arthritis Rheumatol. 2017;69(5):964-975. PMID: 28129527
7. Jiang L, Shang M, Yu S, et al. A high-fiber diet synergizes with Prevotella copri and exacerbates rheumatoid arthritis. Cell Mol Immunol. 2022;19(12):1414-1424. doi: 10.1038/s41423-022-00934-6. PMID: 36323929
8. Zhao T, Wei Y, Zhu Y, et al. Gut microbiota and rheumatoid arthritis: from pathogenesis to novel therapeutic opportunities. Front Immunol. 2022;13:1007165. doi: 10.3389/fimmu.2022.1007165. PMID: 36159786
9. Targeting zonulin and intestinal epithelial barrier function to prevent onset of arthritis. Nat Commun. 2020;11(1):1995. doi: 10.1038/s41467-020-15831-7
10. Martínez-López et al. Intestinal dysbiosis, tight junction proteins, and inflammation in rheumatoid arthritis patients: a cross-sectional study. Int J Mol Sci. 2024;25(16):8649. PMID: 39201332
11. Jarmakiewicz-Czaja S et al. Intestinal permeability disturbances: causes, diseases and therapy. Clin Exp Med. 2024. doi: 10.1007/s10238-024-01496-9. PMID: 39340718
12. Short-chain fatty acids from gut microbiota restore Th17/Treg balance in rheumatoid arthritis: mechanisms and therapeutic potential. Front Immunol. 2025. PMC12482344
13. Henriksson AE, Blomquist L, Nord CE, Midtvedt T, Uribe A. Small intestinal bacterial overgrowth in patients with rheumatoid arthritis. Ann Rheum Dis. 1993;52(7):503-510. PMC1005088
14. Picchianti Diamanti A et al. Impact of Mediterranean diet on disease activity and gut microbiota composition of rheumatoid arthritis patients. Microorganisms. 2020;8(12):1989. doi: 10.3390/microorganisms8121989
15. Casas R et al. Diet as a modulator of intestinal microbiota in rheumatoid arthritis. Nutrients. 2020;12(11):3504. doi: 10.3390/nu12113504. PMID: 33202579
16. Sanchez P, Letarouilly JG, Nguyen Y, et al. Efficacy of probiotics in rheumatoid arthritis and spondyloarthritis: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2022;14(2):354. doi: 10.3390/nu14020354. PMC8779560
17. Zeng L, Deng Y, He Q, et al. Safety and efficacy of probiotic supplementation in 8 types of inflammatory arthritis: a systematic review and meta-analysis of 34 randomized controlled trials. Front Immunol. 2022;13:961325. doi: 10.3389/fimmu.2022.961325. PMC9547048
18. Vaghef-Mehrabany E, Alipour B, Homayouni-Rad A, et al. Probiotic supplementation improves inflammatory status in patients with rheumatoid arthritis. Nutrition. 2014;30(4):430-435. doi: 10.1016/j.nut.2013.09.007. PMID: 24355439